share_log

argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE | 6-K:argenx宣佈VYVDURA注射液在日本獲批皮下注射用於治療全身重症肌無力
SEC announcement ·  01/18 00:00
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息